EGFR-targeted monoclonal antibodies like Cetuximab have improved survival rates in patients, but their effectiveness has been limited by the KRAS activating mutations that confer resistance in approximately 25% of advanced CRC cases [111]. The gene discussed is EGFR; the disease is colorectal carcinoma.